中国临床药理学与治疗学Issue(7)：809-813,5.DOI:10.12092/j.issn.1009-2501.2018.07.014
可溶性人类白细胞抗原G对丙型肝炎初治患者标准化治疗疗效的影响
Effects of soluble human leukocyte antigen G on the standardized treatment of hepatitis C patients
摘要
Abstract
AIM:To investigate the effect of soluble human leukocyte antigen G (s HLA-G) on the efficacy of pegylated interferon combined with ribavirin in the treatment of chronic hepatitis C (CHC).METHODS:A total of 63 CHC patients from October 2013 to October 2015 were enrolled.The genotype of hepatitis C virus (HCV), HCV RNA and s HLA-G were detected by gene chip, RTPCR and ELISA method accordingly.All patients received a subcutaneous injection of pegylated interferon combined with oral ribavirin.The factors affecting the sustained virological response (SVR) were observed and analyzed.RESULTS:The proportion of female and non-genotype 1 in SVR group was significantly higher than that in non-sustained virological response (NSVR) group (female:70.59％ vs.44.83％, χ2= 4.285;non-genotype 1:82.76％ vs.55.88％, χ2= 5.217, P ＜ 0.05);other baseline indexes presented no significant difference (P＞ 0.05).The level of plasma s HLA-G before treatment in NSVR group was significantly higher than that in SVR group[1.85 (1.49-16.00) ng/L vs.1.53 (1.36-2.80) ng/L;U = 329.00, P ＜0.05].After multivariable logistic regression analysis, s HLA-G and HCV genotypes were the independent influencing factors associated with the outcome of treatment with Exp (B) (95％ CI) were0.922 (0.868-0.978) and 14.204 (1.898-106.289), respectively.CONCLUSION:s HLA-G exhibits an important effect on the standardized treatment of hepatitis C patients, and patients with low s HLA-G level are more likely to achieve a sustained virological response.关键词
慢性丙型肝炎/利巴韦林/治疗/聚乙二醇干扰素/可溶性人类白细胞抗原GKey words
chronic hepatitis C/ribavirin/treatment/pegylated interferon/soluble human leukocyte antigen G分类
医药卫生引用本文复制引用
周勇,应莉,徐佳佳,丁世雄,胡爱荣,高国生..可溶性人类白细胞抗原G对丙型肝炎初治患者标准化治疗疗效的影响[J].中国临床药理学与治疗学,2018,(7):809-813,5.基金项目
宁波市自然科学基金(2013A610239) （2013A610239）
浙江省医药卫生省部培育计划基金资助项目(2014PYA018) （2014PYA018）
